The Companies Plan to Jointly Submit a Psilocybin Clinical Trial Application to Health Canada VANCOUVER, BC, Jan. 27, 2022 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce…


Previous articleatai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
Next articleMDMA-Assisted Psychotherapy for PTSD: Interviewing Dr. Rachel Yehuda